Back to MW MARSHALL WACE, LLP

AMLXAMLX
13 quarters

Position history for MWMARSHALL WACE, LLP's holdings in AMYLYX PHARMACEUTICALS INC

No. Marshall Wace exited its AMLX (Amylyx Pharmaceuticals) position in Q2 2025. Its Q1 2025 13F listed 247,275 shares worth $875,353. Marshall Wace already held AMLX in its Q1 2022 13F, the earliest on record, and held it in 10 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$7.5M

Total Shares Change

-584,464

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q2
Latest
Exited
0
-100.0%
$00.0%$6.33
0
2025-Q1
Increased
247,275
+33.9%
$875,3530.0%$3.66
32
2024-Q4
Decreased
184,678
-35.0%
$698,0830.0%$3.84
0
2024-Q3
New
283,986
-
$920,1140.0%$3.08
35
2024-Q1
Exited
0
-100.0%
$00.0%$2.84
0
2023-Q4
Decreased
985,114
-17.8%
$14.5M0.0%$14.72
0
2023-Q3
Decreased
1.2M
-39.5%
$21.9M0.0%$18.31
0
2023-Q2
Increased
2M
+73.8%
$42.7M0.1%$20.98
44
2023-Q1
New
1.1M
-
$33.4M0.1%$27.71
40
2022-Q4
Exited
0
-100.0%
$00.0%$36.95
0
2022-Q3
Decreased
341,064
-48.2%
$9.6M0.0%$30.19
0
2022-Q2
Increased
658,373
+12.7%
$12.7M0.0%$18.18
31
2022-Q1
New
584,464
-
$7.5M0.0%$14.93
38

Other major holders of AMLX: FMR LLC, VIKING GLOBAL INVESTORS LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used